We reported previously in HepG2 cells that estradiol induces cell cycle progression throughout the G 1 -S transition by the parallel stimulation of both PKC-␣ and ERK signaling molecules. The analysis of the cyclin D 1 gene expression showed that only the MAP kinase pathway was involved. Here, the presence of rapid/nongenomic, estradiol-regulated, PI3K/AKT signal transduction pathway, its modulation by the levels of the tumor suppressor PTEN, its cross-talk with the ERK pathway, and its involvement in DNA synthesis and cyclin D 1 gene promoter activity have all been studied in HepG2 cells. 17␤-Estradiol induced the rapid and biphasic phosphorylation of AKT. These phosphorylations were independent of each other, being the first wave of activation independent of the estrogen receptor (ER), whereas the second was dependent on ER. Both activations were dependent on PI3K activity; furthermore, the ERK pathway modulated AKT phosphorylation by acting on the PTEN levels. The results showed that the PI3K pathway, as well as ER, were strongly involved in both G 1 -S progression and cyclin D 1 promoter activity by acting on its proximal region (Ϫ254 base pairs). These data indicate that in HepG2 cells, different rapid/nongenomic estradiol-induced signal transduction pathways modulate the multiple steps of G 1 -S phase transition.
INTRODUCTION
17␤-Estradiol (E2) can trigger DNA synthesis and cell cycle progression in different cell types (Sutherland et al., 1983; Castoria et al., 1999; Marino et al., 2001a) by regulating the expression of the genes involved in the cell cycle machinery (Altucci et al., 1996; Foster et al., 2001) . In particular, E2 can induce cyclin D 1 gene transcription, even though its gene promoter region does not contain any estrogen-responsive element (ERE) or ERE-like sequence (Herbert et al., 1994; Sabbah et al., 1999) , recruiting different transcription factors depending on the cell context. Moreover, the rapid (1-6 h) E2-induced cyclin D 1 gene expression reported in several cell lines, even in the presence of an estrogen receptor lacking the DNA binding domain, suggests that E2-induced rapid/nongenomic mechanisms are sufficient to induce cyclin D 1 overexpression (Marino et al., 2002) . Several cyclin D 1 activation mechanisms have been reported. In particular, we identified the E2-induced rapid extranuclear molecular events in HepG2 cells (e.g., mitogen-activated protein kinase/extracellular regulated kinase [MAPK/ERK] and phospholipase C/protein kinase C [PLC/PKC] activation), showing also that only the E2-induced rapid/nongenomic phosphorylation of ERK was necessary for the E2-induced cyclin D 1 transcription. Furthermore, the destruction of the TRE motif present in the cyclin D 1 promoter, Ϫ848 base pairs (bp), caused the complete loss of estrogen responsiveness. In mammary carcinoma cells, it has been reported (Sabbah et al., 1999; Castro-Rivera et al., 2001; Nagata et al., 2001 ) that the three GC-rich SP1 sites at Ϫ143 to Ϫ110 bp and the CRE motif at Ϫ96 bp regions of the promoter are the major mediators for the induction of the cyclin D 1 promoter by E2 via protein kinase A. In addition, recent data in MCF7 cells indicate a role for the phosphatidylinositol 3-kinase (PI3K) but not for ERK in E2-induced cyclin D 1 Ϫ1800 bp promoter activity (Castoria et al., 2001) .
The PI3Ks compose a family of lipid kinases that phosphorylate the 3Ј position of the inositol ring of the phosphatidyl inositol(4)phosphate (PI-4-P), the phosphatidyl inositol(4, 5)bisphosphate (PI-4,5-P 2 ) to generate PI-3,4-P 2 and PI-3,4,5-P 3 , respectively (Scheid et al., 2002) , which shows an affinity for certain protein modules, such as pleckstrin homology domain, implicated in several cellular processes, including cell survival, DNA synthesis, protein trafficking, and metabolism (for review, see Scheid and Woodgett, 2001) . The role of PI3K in growth involves the serine/threonine kinase, AKT/PKB, translocation in proximity to phosphoinositide-dependent kinase 1, PDK1, resulting in AKT/ PKB phosphorylation (Scheid and Woodgett, 2001) . The PKB/AKT activation drives cells through many biological functions, including gene expression, cell cycle, survival, glucidic metabolism, endocytosis and vesicular trafficking, cell transformation, and oncogenesis (Coffer et al., 1998; Stein and Waterfield, 2000) . AKT/PKB phosphorylation is negatively regulated by the PTEN/MMAC1/TEP1 tumor suppressor gene protein product, which is a phosphatase that dephosphorylates the 3Ј position to reverse the reactions catalyzed by PI3K (Maehama and Dixon, 1998; Cantley and Neel, 1999) . The overexpression of PTEN blocks cell cycle progression and induces apoptosis in cells (Furnari et al., 1998; Ramaswamy et al., 1999) . Although the importance of the PI3K/PTEN pathway in cell growth is well established, its cross-talk with ERK pathway and its role in E2-regulated cyclin D 1 promoter activity are not understood.
In this study, we show that PI3K is required for E2-stimulated HepG2 cell growth. We provide evidence that the ERK pathway rapidly reduces the levels of PTEN, allowing E2-induced phosphorylation of AKT. Our data indicate that both the PI3K and the ERK pathways coordinately regulate cyclin D 1 promoter activity, allowing HepG2 cell cycle progression.
MATERIALS AND METHODS

Reagents
17␤-Estradiol, 17␣-estradiol, gentamicin, penicillin, RPMI-1640 (with or without phenol red), fetal calf serum, and charcoal-stripped fetal calf serum were purchased from Sigma Chemical (St. Louis, MO). The MAP kinase cascade inhibitors PD 98059 and U 0126 and the PI3 kinase inhibitors wortmannin and Ly 294002 were obtained from Calbiochem (San Diego, CA). The estrogen receptor inhibitor ICI 182,780 was obtained from Tocris (Ballwin, MO). Methyl-1-[ 3 H]thymidine (specific activity, 81 Ci/mmol) was purchased from Amersham-Pharmacia (Little Chalfont, UK). Lipofectamine reagent was obtained from Gibco-BRL Life Technology (Gaithersburg, MD). The luciferase kit was obtained from Promega (Madison, WI). The GenElute Plasmid Maxiprep Kit was obtained from Sigma. The Bradford protein assay was obtained from Bio-Rad Laboratories (Hercules, CA). The monoclonal anti-phospho-AKT antibody was obtained from New England Biolabs (Beverly, MA); the monoclonal and polyclonal anti-AKT, anti-PTEN, and anti-␤-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). CDP-Star chemiluminescence reagent for Western blot was obtained from NEN (Boston, MA).
All the other products were from Sigma. Analytical or reagent grade products, without further purification, were used.
Cell Culture
HepG2 cells were grown routinely in 5% CO 2 in air in modified, phenol red-free, RPMI-1640 medium containing 10% (vol/vol) charcoal-stripped fetal calf serum, l-glutamine (2 mM), gentamicin (10 g/ml), and penicillin (100 U/ml). Cells were passaged every 4 d, and media were changed every 2 d.
DNA Synthesis
DNA synthesis was assayed by incubating subconfluent cells (70 -80%) with methyl-1-[ 3 H]thymidine (final concentration, 1 Ci/ml). Cells were treated simultaneously with E2 (final concentration, 10 nM) or vehicle (ethanol/PBS 1:10 vol/vol). Ly 294002 (final concentration, 10 M) or ICI 182,780 (final concentration, 1 M) was added 15 min before E2 and methyl-1-[ 3 H]thymidine. Wortmannin (final concentration, 10 M) was added simultaneously to E2 and labeled thymidine. Thymidine incorporation was assayed 1 h after E2 administration as previously reported (Marino et al., 2001a) .
Plasmids
The gene reporter plasmids pXP2-D 1 -2966-luciferase, pXP2-D 1 ⌬-254-luciferase (Ϫ254), and pXP2-D 1 ⌬-20-luciferase (Ϫ20) and the plasmids containing the vector expression for pCR3.1-␤-galactosidase have been described previously (Herbert et al., 1994; Marino et al., 2002) . Plasmids were purified for transfection with a plasmid preparation kit according to the manufacturer's instructions. A luciferase dose-response curve showed that the maximum effect was present when 1 g of DNA was transfected with 1 g of pCR3.1-␤-galactosidase to normalize transfection efficiency (ϳ55-65%).
Transfection and Luciferase Assay
Cells were grown to ϳ70% confluence, then transfected using Lipofectamine reagent according to the manufacturer's instructions. Six hours after transfection, the medium was changed, and 24 h thereafter, cells were stimulated with 10 nM E2 for 6 h. In some experiments, the HepG2 cells were treated with E2-BSA conjugate (␤-estradiol 6-(0-carboxy-methyl)oxime:BSA, 32 mol E2/mol BSA). This form of macromolecular bound estrogen does not pass through the plasma membrane and is much more water soluble than free E2 (Zheng et al., 1996) . Before each experiment, E2-BSA was dissolved in phenol-free growth medium (0.2 mg/ml), mixed with dextran and charcoal, centrifuged, and passed through a 0.22-mm filter (Russell et al., 2000; Marino et al., 2002; Seo and Leclercq, 2002) . In these conditions, free E2 was retained in the resin (Ͼ3‰) (Stevis et al., 1999) , and the filtrate contained E2-BSA. When indicated, Ly 294002 or wortmannin (PI3K inhibitors) was added 15 min before E2, and reporter plasmid expression was evaluated 6 h thereafter. The cell lysis procedure and the subsequent measurement of luciferase gene expression were performed by use of the luciferase kit according to the manufacturer's instructions with a EC & G Berthold luminometer.
Electrophoresis and Immunoblotting
After treatment with inhibitors (10 M PD 98059 or 10 M U 0126 [MAP kinase cascade inhibitors] or 10 M Ly 294002 or 10 M wortmannin [PI3K inhibitors] or 1 M ICI 182,780) or hormone, cells were lysed as described previously (Marino et al., 2001b) and solubilized in 0.125 M Tris HCl (pH 6.8) containing 10% SDS (wt/vol), 1 mM phenylmethylsulfonyl fluoride, and 5 g/ml leupeptin and boiled for 2 min. Proteins were quantified using the Bradford protein assay (Bradford, 1976) . Solubilized proteins (20 g) were resolved using 7.5% SDS-PAGE at 100 V for 1 h. The proteins were then electrophoretically transferred to nitrocellulose for 45 min at 150 V at 4°C. The nitrocellulose was treated with 3% bovine serum albumin in 138 mM NaCl, 26.8 mM KCl, 25 mM Tris HCl (pH 8.0), 0.05% Tween-20, and 0.1% BSA and then probed at room temperature for 1 h with anti-phospho-AKT, anti-phospho-ERK, or anti-PTEN antibodies. The nitrocellulose was stripped with Restore Western blot stripping buffer (Pierce Chemical, Rockford, IL) for 10 min at room temperature and then probed with anti-AKT (1 g/ ml). Anti-␤-actin antibody (1 g/ml) was used to normalize the sample loading. Antibody reaction was visualized with chemiluminescence reagent for Western blot.
RESULTS
PI3K Is Required for E2-induced DNA Synthesis
To determine whether PI3K is essential for E2-stimulated growth in HepG2 cells, we tested the effect of the selective PI3K inhibitors Ly 294002 and wortmannin on E2-induced DNA synthesis ( 
E2 Rapidly Activates PI3K-dependent AKT Phosphorylation
The serine/threonine kinase AKT/PKB is a major PI3K target, and its activation through the phosphorylation of Thr308/Ser473 mediates many of the downstream cellular effects of PI3K. To investigate the role of the PI3K/AKT pathway in the E2-induced HepG2 cell cycle progression, we analyzed the hormone's effects on AKT activity. Figure  2a shows that E2 stimulated the biphasic phosphorylation of AKT. A transient stimulation was initially detectable after 3 min of hormonal treatment and decreased toward basal levels after 5 min. A second wave of AKT phosphorylation started 10 min after hormone administration, with a peak 30 min later. The total amount of AKT protein did not change, as detected when the same filter was reprobed with anti-AKT antibody.
The specificity of the biphasic E2-induced AKT phosphorylation was confirmed by the powerlessness of the stereoisomer 17-␣-estradiol to induce a similar activation (Figure 2b ).
The role of ER was assessed by using the pure antiestrogen ICI (Figure 3a) . Surprisingly, the ER inhibitor prevented only 30 min E2-induced AKT phosphorylation. To test whether the E2-induced AKT phosphorylation could be mediated by the binding of E2 to the cell surface receptors, HepG2 cells were treated with the E2-BSA conjugate, which does not pass through the plasma membrane (Zheng et Western blot analyses were performed as described in MATERIALS AND METHODS on control (0) and on E2-treated cells (E2) (10 nM) at different times. The same filters were reprobed with anti-AKT antibody. aЈ and bЈ, densitometric analysis (means Ϯ SD) of three independent experiments. *p Ͻ 0.001 compared with respective control values (0), determined using Student's t test. Figure 3b , after E2-BSA stimulation, the increase in the AKT phosphorylation was similar to that induced by the free E2, thus suggesting the probable involvement of a membrane ER in the E2 effects.
1996). As shown in
Consistent with the view that AKT is a target for PI3K, the Ly 294002 and wortmannin pretreatments of HepG2 cells blocked the E2-induced AKT phosphorylation both after 3 min and after 30 min of hormone stimulation (Figure 4 , a and b). The levels of PTEN were analyzed to assess a role for the tumor suppressor PTEN, which recognizes PI-3,4,5-P 3 as the principal substrate in the E2-induced AKT phosphorylation. E2 decreased the PTEN levels at 15 and 30 min after the stimulation, as shown by the time course in Figure 4c .
Cross-Talk Between PI3K and ERK Signal Transduction Pathways and the Effect on the Cyclin D 1 Promoter Activity
The accumulation of cyclin D 1 protein after E2 stimulation is a critical event in G 1 progression. We previously reported The same filters were reprobed with anti-AKT or anti-␤-actin antibodies. aЈ, bЈ and cЈ, densitometric analysis (means Ϯ SD) of three independent experiments. *p Ͻ 0.001 compared with respective control values (0), determined using Student's t test.°p Ͻ 0.001 compared with respective E2 values (E2), determined using Student's t test. the accumulation of E2-induced cyclin D 1 mRNA and protein 1-6 h after hormone stimulation. Furthermore, our data indicated that E2-induced DNA synthesis and cyclin D 1 transcription were strictly dependent on rapid (10 min) and ER-dependent ERK phosphorylation; moreover, we demonstrated that the TRE motif located at Ϫ848 bp of cyclin D 1 promoter was the target for E2-induced ERK activation (Marino et al., 2002) . To assess whether this E2-induced pathway is synergic or parallel to the PI3K pathway in modulating cyclin D 1 transcription, we first examined the effect of the MAP kinase pathway inhibitors on the ERdependent AKT phosphorylation and PTEN levels 30 min after E2 stimulation. The MAP kinase cascade inhibitor (PD 98059 or U 0126) pretreatment completely blocked the E2-induced AKT phosphorylation (Figure 5a ) and caused the parallel increase of PTEN levels (Figure 5b ). The cell pretreatment with the inhibitors alone did not change AKT phosphorylation or PTEN levels.
The pretreatment of HepG2 cells with the PI3K inhibitors Ly 294002 or wortmannin did not affect the E2-induced ERK phosphorylation after 10 min of hormone treatment ( Figure  5c ), even though these concentrations completely blocked AKT phosphorylation.
To verify whether the PI3K signal transduction pathway had a role in regulating cyclin D 1 promoter activity and whether this signaling pathway worked on a different regulatory element(s) present in the cyclin D 1 promoter, we transiently transfected HepG2 cells with either the complete cyclin D 1 promoter construct (Ϫ2966 bp) or the deletion mutants of cyclin D 1 promoter construct (Ϫ254 bp and Ϫ20 bp) linked to luciferase gene. E2 induced the transcription of Ϫ2966 and Ϫ254 cyclin D 1 constructs ( Figure 6, a and b) . PI3K inhibitor pretreatment completely prevented E2 effects on both constructs. Conversely, E2 was ineffective in stimulating the activity of the minimal cyclin D 1 promoter construct (Ϫ20, Figure 6c ).
DISCUSSION
The ER is a ligand-inducible transcriptional enhancer that modulates the transcription of E2-induced target genes. Controversy exists, however, concerning whether E2-activated ER has a role outside the nucleus, particularly in mediating the E2 mitogenic effects (Lee and Yee, 1995; Lupu et al., 1996; Castoria et al., 1999; Marino et al., 2001b; Nadal et al., 2001) . In addition to the accepted model for the E2 action mechanism, there is emerging evidence that E2-regulated mitogenesis starts with the activation of rapid/nongenomic signaling molecules often originating from the cell membrane (Castoria et al., 1999; Marino et al., 2001a Marino et al., , 2001b Marino et al., , 2002 . This activation has been investigated with the primary focus on the MAP kinase pathway in mammary gland cells, MCF7, but with contradictory results (Migliaccio et al., 1996; Improta-Brears et al., 1999; Lobenhofer et al., 2000; Caristi et al., 2001; Castoria et al., 2001) . Similar contradictions, although less well documented, are reported on E2-induced PI3K/AKT activation and on its role in regulating DNA synthesis and the cyclin D 1 promoter activity (Lobenhofer et al., 2000; Castoria et al., 2001; Sun et al., 2001) ; furthermore, an acceptable definition of the cross-talk with other signaling pathways (i.e., MAP kinase) is lacking. The failure in summarizing a general model of E2 action working in MCF7 cells is probably attributable to the changes in the cell context occurring in these cells. Either synchronization procedures or the different ER␣-to-ER␤ ratio present in MCF7 cells, depending on their malignancy (Roger et al., 2001; Liu et al., 2002) , could turn signal transduction pathways on or off differently.
Conversely, the HepG2 cell line represents a valuable experimental model for studying the role played by E2-induced nongenomic actions on hepatic cell proliferation. In fact, these cells retain many of the differentiated characteristics of quiescent hepatocytes, including E2 responsiveness (Archer et al., 1985 (Archer et al., , 1986 Chen et al., 1999; Graf et al., 2001) . Like other liver-derived cells, HepG2 cells cultured in a medium not supplemented with estrogen maintain only the ER␣ expression Couse et al., 1997; Farsetti et al., 1998; Taylor and Al-Azzawi, 2000) , although at levels insufficient to induce a ligand-dependent trans-activation of synthetic ERE-containing target genes (Marino et al., 2001b) . In this experimental model, we have recently identified two nongenomic actions of E2 (PKC-␣ and ERK-2 activation) that work in parallel to modulate distinct steps of E2-induced cell cycle progression (Marino et al., 2002) .
Here, using a pharmacological approach, we found that the disruption of the PI3K cascade by specific inhibitors prevented the ability of HepG2 cells to enter the S phase in response to E2. We also demonstrated that E2 activates the AKT phosphorylation via PI3K and ERK. In fact, only after ERK activation (15 min after E2 administration) was a sustained, ER-dependent AKT phosphorylation detected (15-30 min). The ERK modulation of AKT phosphorylation is connected to the tumor suppressor PTEN levels, as demonstrated by the ability of MAP kinase cascade inhibitors to prevent E2-induced reduction of the PTEN levels. Both the PI3K inhibitors used prevented the cyclin D 1 promoter activity. Noteworthy was the effect also present in the deletion mutant of cyclin D 1 promoter construct (i.e., Ϫ254 bp), which contains the GC-rich region of SP1 and CRE motif.
These results showed a peculiar biphasic PI3K/AKT activation, partially related to PTEN levels, and identified the region of cyclin D 1 promoter affected by this activation cascade. The timing of E2-induced AKT phosphorylation agrees with those reported in MCF7 (i.e., 2-10 min) (Improta-Brears et al., 1999; Castoria et al., 2001) , neuronal, and astroglial cells (from 15 min with the highest level at 30 min) (Ivanova et al., 2002) . Furthermore, we have shown the biphasic AKT phosphorylation with the earliest activation (3 min) to be unresponsive to the pure anti-ER, ICI, and the second (30 min) to be prevented by ICI. No activation was induced after the administration of the stereoisomer 17␣-E2, indicating the specificity of E2-induced AKT phosphorylation. Moreover, both waves of AKT activation were mimicked by the plasma membranenonpermeating E2-BSA and were strictly linked to PI3K. These data, together with the rapidity of AKT phosphorylation (3 and 30 min), imply that the activation of PI3K starts from the plasma membrane. It has been proposed that a putative plasma membrane ER might be involved in rapid/nongenomic effects of E2 in several cell types (Levin, 2002) , although its characterization remains un-E2 Coordinates G 1 -S Phase Transition solved. Recently, a ␥-adrenergic membrane ER, which could be responsible for E2 initiating rapid signal in pancreatic ␤ cells (i.e., increase of Ca 2ϩ entry), has been described (Ropero et al., 2002) . This receptor seems to be structurally unrelated to ER␣, being activated even in the presence of ICI. It is possible that the first activation of AKT, unresponsive to ICI, is dependent on this kind of receptor. By contrast, a fraction of ER␣ appears to be able to translocate from the nucleus (Song et al., 2002) and localize close to the plasma membrane (Norfleet et al., 1999; Marino et al., 2002; Razandi et al., 2002) . This kind of ER could be accounted for in the second wave of AKT phosphorylation.
Conversely, it is known that PI3K catalyzes the phosphorylation in the 3Ј position of the inositol ring of phosphoinositides (mainly PI-4-P and PI-4,5-P 2 ), producing an accumulation of second messengers (i.e., PI-3,4-P 2 , PI-3,4,5-P 3 ) that are poor substrates for PLC but can recruit a variety of cytosolic signaling proteins on plasma membrane. AKT is one of these proteins: the link with the phosphoinositides enables AKT to localize on the plasma membrane and to open up the catalytic site. A second serine/threonine kinase, PDK1, also binds the phosphoinositides and colocalizes with AKT, phosphorylating the activation loop of the exposed catalytic domain (Scheid et al., 2002) . The prevalent paradigm is that AKT phosphorylation is regulated by PTEN levels. Characterization of the lipid phosphatase activity of PTEN demonstrates that it shows specificity for phosphatidyl inositols phosphorylated at the 3Ј position, and indeed, overexpression of PTEN in mammalian cells disrupted the PI3K-dependent production of 4, . Furthermore, the expression of the PTEN catalytically inactive mutant PTEN-C124S, which may function as a substrate trap, resulted in the accumulation of PI-3,4,5-P 3 , indicating that PTEN may function in vivo to antagonize the PI3K-dependent signaling (Furnari et al., 1997; Weng et al., 2001) . These results could explain the presence of the growth factor-induced PI3K/AKT activations, probably mediated by the other PI3K product, PI-3,4-P 2 , which was still observed in the presence of high levels of PTEN (Cantley and Neel, 1999) . In our system, the high levels of PTEN, parallel to the E2-induced earlier AKT phosphorylation, suggest that such activation may be dependent on PI-3,4-P 2 ; furthermore, it is transient and redundant with respect to E2-induced proliferation, because no ER-independent effects on E2-induced DNA synthesis have been detected in HepG2 cells.
The second, prolonged and ER-dependent, AKT phosphorylation may be linked primarily to the production of PI-3,4,5-P 3 ; in fact, it is paralleled by the decrease of PTEN levels. Remarkably, the disruption of the MAP kinase cascade by specific inhibitors prevented the E2-induced PTEN level reduction, suggesting that ERK may modulate the PTEN levels. PTEN was discovered only in 1997, and it has been the focus of particularly intense interest because of its central role in suppressing malignancy, functioning primarily as a PI-3,4,5-P 3 phosphatase to regulate the crucial signal transduction pathway of PI3K (Myers et al., 1998; Yamada and Araki, 2001) . Here, for the first time, a PTEN role in E2-induced cell proliferation has been reported.
Our results show that the disruption of the PI3K cascade by specific inhibitors prevents the E2-induced thymidine incorporation in DNA and confirm the role of cyclin D 1 as a key intermediate in the E2-induced progression of cells through the G 1 phase of the cell cycle, even though no ERE-like sequence in the promoter of cyclin D 1 gene has been detected (Herbert et al., 1994) . The E2 activation of cyclin D 1 promoter is ER dependent, despite the HepG2 cells' containing low levels of ER unable to trans-activate ERE-containing reporter genes. Altogether, these data indicate that E2-induced cyclin D 1 transcription is independent of the DBD domain of ER (Marino et al., 2002) , and we have further demonstrated here that it depends on the rapid/nongenomic effects. The effect of E2 on cyclin D 1 promoter is present with the mutant Ϫ254, which still contains the Oct/Sp1 and the CRE motifs but lacks the TRE, the E2F, and the E-box (Herbert et al., 1994) . All these data sustain the notion that the effect of PI3K pathway on the cyclin D 1 promoter is addressed to the regulatory elements present in this proximal promoter region. Thus, the E2-dependent activation of cyclin D 1 must be considered a multifactorial process involving distinct regulatory elements localized in the cyclin D 1 promoter (Sabbah et al., 1999; Castro-Rivera et al., 2001; Liu et al., 2002) , each of which can be affected by rapid/ nongenomic mechanisms.
In conclusion, E2 induces parallel signaling pathways, which, in turn, play different roles in modulating HepG2 cell proliferation. In particular, the E2-induced PKC-␣ is strongly related to DNA synthesis but is not involved in cyclin D 1 promoter activity (Marino et al., 2002) , which suggests that its role is focused on the steps after cyclin D 1 induction. Conversely, E2-induced MAP kinase and PI3K pathways are strongly involved in both DNA synthesis and cyclin D 1 promoter activity (Marino et al., 2002 and present results) . Altogether, these findings, summarized in Figure 7 , represent a new model of E2-induced cell proliferation. 
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